Insulin Aspart (CAT#: TP-003CL)
Insulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. It has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin. Insulin aspart is produced in a genetically modified strain of Saccharomyces cerevisiae and harvested from a bioreactor.
Specifications
- Classify
- Protein therapeutics replacing a protein that is deficient or abnormal: Endocrine disorders (hormone deficiencies)
- Therapeutic
- Insulin aspart; insulin glulisine; insulin lispro
- Trade Name
- Novolog (Aspart), Apidra (Glulisine), Humalog (Lispro)
- Function
- Insulin analogues with faster onset of action and shorter duration of action
- Examples of clinical use
- Diabetes mellitus
References
- Synonyms
- Aspart, Aspart Insulin, B28-Aspart-Insulin, INA-X14, Insulin aspart protamine recombinant, Insulin aspart recombinant, Insulin X14, Insulin, Asp(B28)
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TP-003CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.